Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A SIRT7-dependent acetylation switch regulates early B cell differentiation and lineage commitment through Pax5

  • Gamez-Garcia, Andrés|||0000-0003-4927-3678
  • Espinosa-Alcantud, María Dolores|||0000-0002-1126-2458
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Alari Pahissa, Elisenda|||0000-0001-7424-5383
  • Marazuela-Duque, Anna
  • Thackray, Joshua K.|||0000-0003-2828-452X
  • Ray, Chandni
  • Berenguer Balaguer, Clara
  • Kumari, Poonam
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Braun, Thomas|||0000-0002-6165-4804
  • Ianni, Alessandro|||0000-0001-7398-589X
  • Tischfield, Jay A.|||0000-0003-3217-8287
  • Serrano, Lourdes
  • Esteller, M.|||0000-0003-4490-6093
  • Sardina, José Luis|||0000-0002-8493-3937
  • De La Torre, Carolina
  • Sigvardsson, Mikael|||0000-0001-8527-7276
  • Vazquez Prat, Berta Nieves|||0000-0002-8164-3926
  • Vaquero, Alejandro|||0000-0002-8735-4156
B lymphopoiesis is orchestrated by lineage-specific transcription factors. In B cell progenitors, lineage commitment is mediated by Pax5, which is commonly mutated in B cell acute lymphoblastic leukemia. Despite its essential role in immunity, the mechanisms regulating Pax5 function remain largely unknown. Here, we found that the NAD-dependent enzyme SIRT7 coordinates B cell development through deacetylation of Pax5 at K198, which promotes Pax5 protein stability and transcriptional activity. Neither Pax5 deacetylated nor acetylated mimics rescued B cell differentiation in Pax5 pro-B cells, suggesting that B cell development requires Pax5 dynamic deacetylation. The Pax5 deacetylation mimic restored lineage commitment in Pax5 pro-B cells and B cell differentiation in Sirt7 pro-B cells, suggesting the uncoupling of differentiation from lineage commitment. The SIRT7-Pax5 interplay was conserved in B cell acute lymphoblastic leukemia, where SIRT7 expression correlated with good prognosis. Our findings reveal a crucial mechanism for B lymphopoiesis and highlight the relevance of sirtuins in immune function.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

  • Martinez-Verbo, Laura
  • Veselinova, Yoana|||0000-0003-4124-9788
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • Pato, Miguel L.|||0000-0001-8840-7259
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Villanueva, Lorea|||0000-0003-1858-7076
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Cardus, Oriol|||0000-0002-5446-5423
  • Salsench, Sergi V.|||0000-0002-4390-6887
  • García-Ortiz, Almudena
  • Valeri, Antonio
  • Rojas, Elizabeta A.
  • Barrena, Naroa|||0000-0003-4324-3371
  • Gutiérrez, Norma C.
  • Prósper, Felipe
  • Agirre, Xabier|||0000-0002-6558-9560
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Esteller, M|||0000-0003-4490-6093
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Clinical Perspectives in Epitranscriptomics

  • Santos-Pujol, Eloy|||0000-0002-7788-6562
  • Quero-Dotor, Carlos|||0000-0002-3951-2287
  • Esteller, M|||0000-0003-4490-6093
Epitranscriptomics, the study of reversible and dynamic chemical marks on the RNA, is rapidly emerging as a pivotal field in post-transcriptional gene expression regulation. Increasing knowledge about epitranscriptomic landscapes implicated in disease pathogenesis proves an invaluable opportunity for the identification of epitranscriptomic biomarkers and the development of new potential therapeutic drugs. Hence, recent advances in the characterization of these marks and associated enzymes in both health and disease blaze a trail toward the use of epitranscriptomics approaches for clinical applications. Here, we review the latest studies to provide a wide and comprehensive perspective of clinical epitranscriptomics and emphasize its transformative potential in shaping future health care paradigms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-Cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy

  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Casado Pelaez, Marta|||0000-0002-8428-8384
  • Davalos, Veronica|||0000-0003-4077-5137
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Mata, Caterina|||0000-0001-9403-7434
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Roué, Gaël|||0000-0003-0245-2257
  • Valcárcel, David|||0000-0002-8747-078X
  • Molero, Antonieta|||0000-0002-3735-465X
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Acha, Pamela|||0000-0002-4528-1219
  • Manzanares Mileo, Ana|||0000-0003-4125-4675
  • Tobiasson, Magnus|||0000-0002-3633-5852
  • Hellström-Lindberg, Eva|||0000-0002-7839-3743
  • Sole, F|||0000-0002-3251-2161
  • Esteller, M|||0000-0003-4490-6093
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMAs), such as azacitidine (AZA), have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia (AML). However, our capacity to identify who will respond to HMAs, and the duration of response, remains limited. To shed light on this question, we have leveraged the unprecedented analytical power of single-cell technologies to simultaneously map the genome and immunoproteome of MDS samples throughout clinical evolution. We were able to chart the architecture and evolution of molecular clones in precious paired bone marrow MDS samples at diagnosis and post-treatment to show that a combined imbalance of specific cell lineages with diverse mutational profiles is associated with the clinical response of MDS patients to hypomethylating therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine, A multicentre retrospective study

  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Davalos, Veronica|||0000-0003-4077-5137
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Valcárcel, David|||0000-0002-8747-078X
  • Molero, Antonieta|||0000-0002-3735-465X
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Gattermann, Norbert
  • Wulfert, Michael
  • Chaparro, Lorea
  • Sole, F.|||0000-0002-3251-2161
  • Cabezón, Marta|||0000-0001-5122-7481
  • Jiménez-Lorenzo, María J.
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Zamora, Lurdes|||0000-0003-1713-7110
  • De Stefano, Alessia
  • Casalin, Irene
  • Finelli, C.
  • Follo, Matilde Y.
  • Esteller, M.|||0000-0003-4490-6093
Real-world data have revealed that a substantial portion of patients with myelodysplastic syndromes (MDS) does not respond to epigenetic therapy with hypomethylating agents (HMAs). The cellular and molecular reasons for this resistance to the demethylating agent and biomarkers that would be able to predict the treatment refractoriness are largely unknown. In this study, we shed light on this enigma by characterizing the epigenomic profiles of patients with MDS treated with azacitidine. Our approach provides a comprehensive view of the evolving DNA methylation architecture of the disease and holds great potential for advancing our understanding of MDS treatment responses to HMAs.